로타바이러스 백신 접종 유무 및 백신종류에 따른 창자겹침증 발병 연령의 비교: 단일기관 연구
Difference in the distribution of onset age of intussusception after rotavirus vaccination and according to the type of rotavirus vaccine: single medical center study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Rotavirus is the most common cause of severe gastroenteritis in children <5 years of age. The first vaccine, RotaShield was developed, but withdrawn because of its association with increased risk of intussusception. Then, RotaTeq and Rotarix were developed. Although in pre-licensure studies, they were not associated with an increased risk of intussusceptions, in recent studies, it has been controversial. Regarding increased risk of intussusception, we studied the difference in the age of intussusception after rotavirus vaccination. Methods: A retrospective analysis was conducted on 136 patients diagnosed with intussusception at Yeungnam University Medical Center for 4 years in the pre-vaccination period (group A) and in the post vaccination period (group B). Sex, mean age and age distribution of intussusceptions were compared according to the type of rotavirus vaccine (group B-1, RotaTeq; group B-2, Rotarix). Results: The median ages of group A and group B were 18.8±19.6 months and 15.5±10.2 months, with no significant differences (p=0.23). The median ages of group B-1 and group B-2 were 15.3±9.3 months and 15.6±10.8 months, with no significant differences (p=0.91). And No significant difference in the distribution of onset age was observed between groups, and only 6 patients were diagnosed with intussusceptions within 1 month after vaccination. Conclusion: No difference was observed in the distribution of onset age of intussusception after rotavirus vaccination and according to the type of rotavirus vaccine. Our study has a limitation in that it was conducted in part of the Daegu area. Additional study is needed.
Abstract
Background: Rotavirus is the most common cause of severe gastroenteritis in children <5 years of age. The first vaccine, RotaShield was developed, but withdrawn because of its association with increased risk of intussusception. Then, RotaTeq and Rotarix were developed. Although in pre-licensure studies, they were not associated with an increased risk of intussusceptions, in recent studies, it has been controversial. Regarding increased risk of intussusception, we studied the difference in the age of intussusception after rotavirus vaccination. Methods: A retrospective analysis was conducted on 136 patients diagnosed with intussusception at Yeungnam University Medical Center for 4 years in the pre-vaccination period (group A) and in the post vaccination period (group B). Sex, mean age and age distribution of intussusceptions were compared according to the type of rotavirus vaccine (group B-1, RotaTeq; group B-2, Rotarix). Results: The median ages of group A and group B were 18.8±19.6 months and 15.5±10.2 months, with no significant differences (p=0.23). The median ages of group B-1 and group B-2 were 15.3±9.3 months and 15.6±10.8 months, with no significant differences (p=0.91). And No significant difference in the distribution of onset age was observed between groups, and only 6 patients were diagnosed with intussusceptions within 1 month after vaccination. Conclusion: No difference was observed in the distribution of onset age of intussusception after rotavirus vaccination and according to the type of rotavirus vaccine. Our study has a limitation in that it was conducted in part of the Daegu area. Additional study is needed.
참고문헌 (17)
- Parashar UD, "Value of post-licensure data on benefits and risks of vaccination to inform vaccine policy: the example of rotavirus vaccines", Vaccine, 33(Suppl 4), pp.D55~D59 (2015)
- Dennehy PH, "Rotavirus vaccines--an update", Vaccine, 25, pp.3137~3141 (2007)
- Rha B, "Intussusception following rotavirus vaccination: an updated review of the available evidence", Expert Rev Vaccines, 13, pp.1339~1348 (2014)
- Kim CH, "Up-to-date knowledge of rotavirus vaccine", J Soonchunhyang Med Sci, 14, pp.143~152
- Yih WK, "Intussusception risk after rotavirus vaccination in U.S. infants", N Engl J Med, 370, pp.503~512 (2014)
- Escolano S, "Intussusception after rotavirus vaccination--spontaneous reports", N Engl J Med, 365, pp.2139~ (2011)
- Escolano S, "Intussusception risk after RotaTeq vaccination: evaluation from worldwide spontaneous reporting data using a self-controlled case series approach", Vaccine, 33, pp.1017~1020 (2015)
- Weintraub ES, "Risk of intussusception after monovalent rotavirus vaccination", N Engl J Med, 370, pp.513~519 (2014)
- Velázquez FR, "Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico", Pediatr Infect Dis J, 31, pp.736~744 (2012)
- Yung CF, "Intussusception and monovalent rotavirus vaccination in Singapore: self-controlled case series and risk-benefit study", J Pediatr, 167, pp.163~168 (2015)
- Clark A, "Evaluating the potential risks and benefits of infant rotavirus vaccination in England", Vaccine, 32, pp.3604~3610 (2014)
- Murphy TV, "Intussusception among infants given an oral rotavirus vaccine", N Engl J Med, 344, pp.564~572 (2001)
- Ruiz-Palacios GM, "Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis", N Engl J Med, 354, pp.11~22 (2006)
- Vesikari T, "Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study", Lancet, 370(9601), pp.1757~1763 (2007)
- Vesikari T, "Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine", N Engl J Med, 354, pp.23~33 (2006)
- "Rotavirus vaccines: an update", Wkly Epidemiol Rec, 84, pp.533~540 (2009)
- Anderson EJ, "Intussusception risk increased after rotavirus vaccination but outweighed by benefits", Evid Based Med, 19, pp.191~192 (2014)